Xcout Intel
Alterome Therapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Alterome Therapeutics, Inc. among biotech companies — ranked by similarity to what Alterome Therapeutics, Inc. actually does, not by market-cap band.
Subscribe to see Alterome Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Alterome Therapeutics, Inc.
Alterome Therapeutics, Inc. is a clinical-stage precision oncology company headquartered in San Diego, California, founded in 2021. The privately held biotech firm focuses on developing targeted therapies to address genomically defined cancer drivers and intractable oncological targets.
Alterome Therapeutics, Inc. at a glance
Alterome Therapeutics, Inc. is a biotech company headquartered in United States. Its most recent funding round, Series B, raised $132M in April 2024. Xcout tracks 25 named people at Alterome Therapeutics, Inc., including Jung Choi (CEO). Xcout recorded 2 job postings from Alterome Therapeutics, Inc. in the last 90 days.
Alterome Therapeutics, Inc. leadership
- Jung ChoiCEO
- Scott MoorefieldCOO & CBO
- Johanna MyletCFO
- Leonardo FaoroCMO
- Ryan Corcoran, MD, PhDCo-founder, SAB Chair
- John HuangSVP, Biology
19 more named people on record for Alterome Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Alterome Therapeutics, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $132M | — | |
| Series A | $100M | — | |
| SEC Form D filing | $63.8M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Alterome Therapeutics, Inc.
Xcout recorded 2 job postings from Alterome Therapeutics, Inc. in the last 90 days, from a hiring record Xcout has kept since July 2026.
The weekly hiring trend, the roles and locations behind it — see Alterome Therapeutics, Inc.'s hiring signals →
Top 12 Alterome Therapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to Alterome Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Apeiron Therapeutics is a clinical-stage biopharmaceutical and precision oncology company focused on developing biomarker-driven therapeutics for cancer.
Biotechnology
Turning Point Therapeutics is a clinical-stage precision oncology company based in San Diego, California, that designs and develops targeted cancer therapies. Founded in 2013, the company operates as a subsidiary of Bristol Myers Squibb following its acquisition in 2022.
Similar biotech company
AUM Biosciences is a clinical-stage biotechnology company that develops precision oncology therapeutics utilizing multi-faceted inhibition strategies to overcome cancer drug resistance. The company serves patients and the healthcare sector by advancing a targeted clinical pipeline designed to combat tumor evasion and treatment resistance.
Similar biotech company
Mirador Therapeutics, Inc. is a clinical-stage precision medicine company headquartered in San Diego, California, focused on developing first- and best-in-class next-generation therapeutics.
Similar biotech company
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
Life Sciences
OncXerna Therapeutics is a clinical-stage precision-oncology biotechnology company that develops RNA-based biomarkers and targeted cancer therapies. Its work is intended to help identify cancer patients most likely to benefit from particular treatments and support oncologists and pharmaceutical partners in treatment selection.
Similar biotech company
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.
Biotechnology
Edison Oncology Holding Corp is a clinical-stage biopharmaceutical company that develops first-in-class, small-molecule, biomarker-driven therapies to target major cancer markets. The company identifies, acquires, and advances underdeveloped drug candidates to address critical unmet needs for cancer patients with specific genetic mutations.
Similar biotech company
Orum Therapeutics is a biotechnology research company specializing in the development of targeted protein degraders for precision oncology using its TPD² approach. The company is headquartered in Daejeon, South Korea, with additional offices in Boston, Massachusetts.
Biotechnology
CatchMe Therapeutics is a biotechnology company headquartered in Ness Ziona, Israel, founded in August 2021. The firm develops RNA-based medicines and precision medicine solutions focusing on RNA-binding proteins for cancer-related therapies.
Biotechnology
DCx Biotherapeutics is a Canadian preclinical-stage biotechnology company developing precision oncology therapeutics and precision drug conjugates to target genetically defined cancers. The company focuses on addressing root drivers and key cellular interdependencies of cancer lesions.
Similar biotech company
Fore Biotherapeutics is a virtual precision oncology company rooted in science and innovation, with expertise and talent across the USA. The company is focused on developing treatments, including its Plixorafenib Program.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Alterome Therapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Alterome Therapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →